X4 Pharmaceuticals Inc expected to post a loss of 15 cents a share - Earnings Preview

X4 Pharmaceuticals

19/03/2024 12:38

* X4 Pharmaceuticals Inc  XFOR.OQ   XFOR.O  is expected
to show no
change in quarterly revenue when it reports  results on March 21
for the period ending December 31 2023
    * 
    * ​LSEG's mean analyst estimate for X4 Pharmaceuticals Inc
is for
a loss of 15 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for X4
Pharmaceuticals Inc is $3.00​, above​ its last closing price
of $0.92. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.15       -0.15      -0.01     Beat    93.3
 Jun. 30 2023  -0.16       -0.16      -0.33     Missed  -102
 Mar. 31 2023  -0.21       -0.22      -0.16     Beat    26.3​
 Dec. 31 2022  -0.21       -0.24      -0.29     Missed  -20.2
 ​​Sep.        -0.31       -0.30      -0.26     Beat    13.1
 30 2022                                                
 Jun. 30 2022  -0.65       -0.64      -0.60     Beat    6​
 Mar. 31 2022  -0.60       -0.61      -0.72     Missed  -18.3
 Dec. 31 2021              -0.68      -0.90     Missed  -31.8
 This summary was machine generated March 19 at 12:38 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)